

Morning Wrap

Today's Newsflow

Select headline to navigate to article

DCC Best Buy Positive Read across for Technology Division **UK Economic view** Prices down in August, but have remained relatively resilient

Equity Research

30 Aug 2024

08:26

Upcoming Events

Company Events	
2-Sep	Kainos Group; Q125 Trading Update
3-Sep	DS Smith; Q125 Trading Update
	Uniphar; Q224 Results
04-Sep	Bakkavor Group; Q224 Results
	Barratt Developments; FY24 Results
	Cairn Homes; Q224 Results
	Dalata Hotel Group; Q224 Results
	Datalex; Q224 Results
	Frontier Developments; FY24 Results
05-Sep	Darktrace; FY24 Results Glenveagh Properties; Q224 Results Vistry Group; Q224 Results

Economic Events		
Ireland	Retail Sales Jul	
United Kingdom		
30-Aug	BoE Mortgage Approvals M4 Money Supply	
United States		
Europe		

Goodbody Capital Markets

Equity Research +353 1 6419221 Equity Sales +353 1 6670222 Bloomberg RESP GDSE<GO>

Goodbody Stockbrokers UC, trading as Goodbody, is regulated by the Central Bank of Ireland. In the UK, Goodbody is also subject to regulation by the Financial Conduct Authority. Goodbody is a member of Euronext Dublin and the London Stock Exchange. Goodbody is a member of the group of companies headed by AIB Group plc. For the attention of US clients of Goodbody Securities Inc, this third-party research report has been produced by our affiliate, Goodbody Stockbrokers

Recommendation: Buy Closing Price: £53.50

kenneth.rumph@goodbody.ie

Kenneth Rumph +44 7442610768

DCC Best Buy Positive Read across for Technology Division

DCC's Technology division (24% of FY24 YE March sales, 13% of FY24 OP) has been the part of DCC's business under pressure in recent periods, under pressure from consumer and commercial spending.

In this context, US peer Best Buy (BBY), addressing the US consumer technology market, yesterday saw a 14% stock price bounce, after 2Q24 numbers beating and a statement talking about a "confluence of replacement, upgrade, and innovation in the coming years", also calling out some AI-based product innovation coming to market. This is a positive read through for DCC as we see FY25 (March YE) as a year of stabilisation (sales +2% after -9% organic in FY24) and our estimates don't currently assume any acceleration in sales growth or improvement in operating margins in FY26 – BBUY would suggest this is cautious, especially beyond the still uncertain 2024 holiday sales season.

DCC is trading just below 11x FY25E EPS v's 14-16x historic, while delivering cash and earnings consistent with its past record. Despite a period of heavy investment (two healthcare plants) and associated cost annualization effects still to work through, ROCE has remained strong at over 14% and is set to trend up.

Home...

UK Economic view Prices down in August, but have remained relatively resilient

House prices in the UK fell by 0.2% mom in August (+0.2% expected) according to Nationwide. It still meant that annual growth rose to 2.4% (from 2.1% in July), due to weak base effects. This is the highest annual rate of growth since late 2022.

There are opposing drivers of house prices in the UK at the current time. On the positive side, nominal earnings growth continues to grow at a decent clip in a labour market that remains tight. Mortgage rates are high relative to the recent past but have started to come down as the Bank of England has started to reduce Bank Rate. However, affordability remains stretched. Nationwide's measure of affordability (house price/income) stands at c.6x currently, having peaked at c.7x in 2023. This is still well ahead of the long-run average is 4.5x but closing in on the average since 2000 of c.5.5x. In the absence of a demand shock, it is difficult to see nominal price declines improving this picture. More likely is a continuation of the recent trend whereby income growth exceeds house price growth leading to a further improvement in the ratio.

The UK housing market has been relatively resilient through the period of interest rate rises by the Bank of England. Following the close call rate cut this month, the market is pricing in another rate cut in November, with one full percentage point cut priced in the next twelve months. In this environment, we would expect some pick up in mortgage demand and for prices to remain relatively resilient. Dermot O'Leary +353-1-641 9167 dermot.c.oleary@goodbody.ie

Home...

Issuer & Analyst Disclosure

Analyst Certification

The named Research Analyst certifies that: (1) All of the views expressed in this research report accurately reflect my personal views about any and all of the subject securities and issuers. (2) No part of my remuneration was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by me in this report.

Regulatory Information

Goodbody Stockbrokers UC, trading as Goodbody, is regulated by the Central Bank of Ireland. In the UK, Goodbody is also subject to regulation by the Financial Conduct Authority. Goodbody is a member of Euronext Dublin and the London Stock Exchange. Goodbody is a member of the group of companies headed by AIB Group plc. This publication has been approved by Goodbody. The information has been taken from sources we believe to be reliable, we do not guarantee their accuracy or completeness and any such information may be incomplete or condensed. All opinions and estimates constitute best judgement at the time of publication and are subject to change without notice. The information, tools and material presented in this document are provided to you for information purposes only and are not to be used or considered as an offer or the solicitation of an offer to sell or to buy or subscribe for securities.

Conflicts of Interest

Goodbody has procedures and policies in place to identify and manage any potential conflicts of interest that arise in connection with its research business. Goodbody analysts and other staff who are involved in the preparation and dissemination of research operate and have a management reporting line that is independent to its business. Information barriers are in place between the Corporate Finance arm and the Research arm to ensure that any confidential and or price sensitive information is handled in an appropriate manner.

Our Investment Research Conflicts of Interest Policy is available at Conflicts of Interest

Investors should be aware, that, where appropriate, research may be disclosed to the issuer(s) in advance of publication, in order to correct factual inaccuracies only and not to materially amend the research in any way. Goodbody is satisfied that it has operational procedures in place, which ensure that such disclosures will not compromise the report's objectivity.

The list of companies for which Goodbody acts as market maker and on which it provides research, is available at Regulatory Disclosures

Other disclosures

A description of this company is available at Company Descriptions

All prices used in this report are as at close of business of the previous working day unless otherwise indicated.

The time of publication of the report is Irish Standard Time (UTC +1), which accounts for transitions between IST and GMT (i.e. daylight saving time).

A summary of our standard valuation methods are available at Valuation Methodologies

A summary of share price recommendations and whether material investment banking services have been provided to these companies is available at <u>Regulatory Disclosures</u>

Other important disclosures are available at Regulatory Disclosures

Goodbody updates its recommendations on a regular basis. A breakdown of all recommendations provided by Goodbody is available at <u>Regulatory Disclosures</u> Where Goodbody has provided investment banking services to an issuer, details of the proportion of buys, holds and sells attributed to that issuer will also be included. This is updated on a quarterly basis.

Recommendation Definitions

Goodbody uses the terms "Buy", "Sell" and "Hold. The term "Buy" means that the analyst expects the security to appreciate in excess of 10% over a twelve month period. The term "Sell" means that the security is expected to decline in excess of 10% over the next twelve months. The term "Hold" means that the analyst expects the security to neither appreciate more than 10%, or depreciate more than 10% over the next twelve months.

On 26th November, 2012, the terms "Add" and "Reduce" were removed from the Recommendation Definitions and both were replaced with the "Hold" recommendation. Any Previous Recommendation that refers to either an "Add" means that the analyst expected the security to appreciate by up to 15% over a twelve month period. Any Previous Recommendation to "Reduce" means that the analyst expected the security to decline by up to 15% over the next twelve months.

In the event that a stock is delisted the firm will automatically cease coverage. If however the firm ceases to cover a stock for any other reason the firm will disclose this fact.

Distribution of research to clients of Goodbody Securities Inc (GSI) in the US

GSI distributes third-party research produced by its affiliate, Goodbody GSI is a member of FINRA and SIPC GSI does not act as a market-maker.

This information was current as of the last business day of the month preceding the date of the report.

An affiliate of GSI may have acted, in the past 12 months, as lead manager/co-lead manager of a publicly disclosed offer of the securities in this company. Investors should be aware that an affiliate of GSI may have provided investment banking or non-investment-banking services to, and received compensation from this company in the past 12 months or may provide such services in the next three months. The term investment banking services includes acting as broker as well as the provision of corporate finance services, such as underwriting and managing or advising on a public offer. All transactions by US persons involving securities of companies discussed in this report are to be effected through GSI.

Disclaimer

While all reasonable care has been taken in the production and dissemination of this report it is not to be relied upon in substitution for the exercise of independent judgement. Nothing in this report constitutes investment, legal, accounting or tax advice, or a representation that any investment or strategy is suitable or appropriate to your individual circumstances, or otherwise constitutes a personal recommendation to you.

Private customers having access, should not act upon it in anyway but should consult with their independent professional advisors. The price, value and income of certain investments may rise or may be subject to sudden and large falls in value. You may not recover the total amount originally invested. Past performance should not be taken as an indication or guarantee of future performance; neither should simulated performance. The value of securities may be subject to exchange rate fluctuation that may have a positive or adverse effect on the price or income of such securities.

All material presented in this report, unless specifically indicated otherwise is copyright to Goodbody. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of Goodbody.